Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by SizzlinSteakson Nov 30, 2017 3:48pm

90 Views

Post# 27066741

I'm in at 13

I really like this one. It is one of the few cannabis stocks that hasn't exploded yet and it is at a great stage with plenty of catalysts... closing PP, announcement of phase 2 trial and many other possible indications. Just like all the other cannabis I anticipate this one will also run hard in the coming days or weeks. Seems like a no brainer at these levels. Amazing buy here.

Just look at WEED, BLO, APP, NAC, TNY, and so many others.... KALY is in line. Some big $$$ to be made here.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal